1452 Pembrolizumab (MK-3475) in Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma

Page last updated: 22 November 2016

Application Detail



Description of Medical Service

ImmunoHistoChemistry (IHC) test for identification of Mismatch Repair Deficiency (dMMR) for access to pembrolizumab in patients with Stage IV CRC

Description of Medical Condition

Stage IV Colorectal Carcinoma (CRC) who are receiving first line (1L) treatment

Reason for Application

Amendment to MBS item

Medical Service Type

Co-dependent technology

Previous Application Number

Not Applicable

Associated Documentation

Application Form

Application form (PDF 271 KB)
Application form (Word 544 KB)

PICO Confirmation

PICO Confirmation (PDF 582 KB)
PICO Confirmation (Word 256 KB)

Assessment Report


Public Summary Document


Meetings for this Application


8 December 2016